Serum Interleukin - 17A in Juvenile Idiopathic Arthritis

January 15, 2023 updated by: Mennat-Allah Khaled Tolba Abdelraheem, Assiut University
  1. This study aims to determine the serum levels of interleukin-17A (IL-17A) in children with juvenile idiopathic arthritis (JIA)
  2. Analyze the correlation between IL-17A values and disease activity, certain clinical features, and laboratory markers of inflammation.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Juvenile Idiopathic Arthritis (JIA) is a group of chronic heterogenous disorders that manifests as joint inflammation in patients aged <16 years and lasts longer than 6 weeks. Globally, approximately 3 million children and young adults are suffering from JIA with prevalence rates consistently higher in girls. The prevalence of JIA in Africa and Middle East was observed to be towards the lower range of the global estimate. (1) The precise cause and pathogenesis of JIA are unknown; however, genetic, environmental, and autoimmune factors are hypothesized to play a role in its development. (2) The condition can affect one or more joints and cause systemic symptoms such as fever or rash, as well as extra-articular inflammatory signs such as uveitis.(3)

The IL-17 cytokine superfamily is composed of 6 structurally related cytokines, namely IL-17A-F. The most investigated member of the family is IL-17A. It is synthesized by Th17 cells, γδ-T cells, NK T cells, lymphoid tissue inducer-like cells, Paneth cells, and neutrophils. IL-17A plays important roles in protection from bacterial and fungal infections and in the development of autoimmune diseases (4)

Recently, a number of studies have been conducted on the role of IL-17A in the development of chronic arthritis. It has a role both at the initial stages of joint inflammation and in the destruction of joint cartilage and bone structures.(5) It binds to its receptors on synoviocytes, endothelial cells, fibroblasts and osteoblasts and stimulates production of pro-inflammatory cytokines, chemokines and other inflammatory mediators, and also, interacts synergistically with other pro- inflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor alpha.(6)

Study Type

Observational

Enrollment (Anticipated)

78

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 16 years (Child)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients less than 16 years at onset of disease and diagnosed with oligoarticular and polyarticular JIA, fulfilling the ILAR classificationcriteria of JIA.

Description

Inclusion Criteria:_ Patients less than 16 years at onset of disease and diagnosed with oligoarticular and polyarticular JIA, fulfilling the ILAR classificationcriteria of JIA.

  • Control group will include age-and-sex-matched apparently healthy children.

Exclusion Criteria: • Patients having associated neurological or disabling diseases.

  • Patients with diabetes mellitus, acute or chronic infections.
  • Patients with another causes of arthritis other than JIA.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum Interleukin - 17A in juvenile idiopathic Arthritis
Time Frame: baseline

This study aims to determine the serum levels of interleukin-17A (IL-17A) in children with juvenile idiopathic arthritis (JIA)

-Analyze the correlation between IL-17A values and disease activity, certain clinical features, and laboratory markers of inflammation
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

February 1, 2023

Primary Completion (Anticipated)

May 1, 2025

Study Completion (Anticipated)

September 1, 2025

Study Registration Dates

First Submitted

January 7, 2023

First Submitted That Met QC Criteria

January 15, 2023

First Posted (Actual)

January 18, 2023

Study Record Updates

Last Update Posted (Actual)

January 18, 2023

Last Update Submitted That Met QC Criteria

January 15, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Interleukin - 17A in JIA

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on JIA

Clinical Trials on serum levels of interleukin-17A in JIA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe